In re­ver­sal, NICE backs Rubra­ca af­ter Clo­vis agrees to a price cut

NICE has changed its mind, agree­ing to cau­tious­ly en­dorse Clo­vis On­col­o­gy’s Rubra­ca af­ter the drug­mak­er agreed to cut its price — about two months af­ter the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.